Science brief
Metabolic Repurposing and Neuro-Immunology
Weizmann Institute breakthroughs target cancer metastasis with sildenafil and validate immune-checkpoint therapy for Alzheimer's disease.
Science
Targetable metabolic vulnerabilities can be disrupted by repurposed drugs — offering a novel strategy to prevent tumor spreading without developing expensive new molecules.
BackgroundCancer metastasis remains responsible for the majority of cancer-related fatalities, as detached tumor cells travel through the bloodstream to seed distant organs. Metabolic repurposing of non-oncology medications offers an expedited path to novel clinical trials.
- The study published in Cancer Research demonstrates that sildenafil starves migrating tumor cells of necessary cholesterol lipids, cutting off the structural fuels required to move.
- Researchers observed reduced metastatic spread across multiple solid tumor models during preclinical testing, opening the door for combination therapy trials.
- The findings emphasize how non-oncology drugs can be leveraged to target host metabolic pathways without compounding chemotherapy toxicity, potentially lowering drug development costs.
Science
Immune-checkpoint targeting in neurodegeneration is showing early safety success — opening a fresh therapeutic alternative to plaque-removal antibodies.
BackgroundCo-founded by Weizmann Institute Professor Michal Schwartz, ImmunoBrain Checkpoint departs from traditional amyloid-clearing strategies. Instead, it temporarily blocks PD-L1 signals to encourage immune cell migration into the central nervous system.
- Results published in Nature Medicine showed downward trends in neuronal damage biomarkers at maximum dosage levels, validating the immune-checkpoint mechanism in human subjects.
- Trial participants experienced no instances of amyloid-related imaging abnormalities, such as brain swelling or microbleeds, which frequently plague conventional antibody treatments.
- The study was conducted in collaboration with Tel Aviv Medical Center and University College London researchers, laying groundwork for broader international Phase 2 testing.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.